Billings LK, et al. - A comparative scrutiny was conducted of the efficacy and safety of initiating insulin degludec/liraglutide fixed-ratio combination (IDegLira) vs basal-bolus insulin in patients with uncontrolled type 2 diabetes on insulin glargine (IGlar U100) 20–50 units/day and metformin. Findings demonstrated that IDegLira treatment elicited HbA1c reductions that were comparable to basal-bolus, displaying statistically superior lower hypoglycemia rates and weight loss vs weight gain in the study cohort.